Clinical Trial Update: Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis [Phase 2, Phase 3]

View source ↗

Summary

This entry notes a long-term extension study of Ulviprubart (ABC008) in Inclusion Body Myositis, spanning Phase 2 and Phase 3, which is currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inclusion Body Myositis

Drugs mentioned

• Ulviprubart

Snippet

Sponsor: Abcuro, Inc. | Conditions: Inclusion Body Myositis (IBM) | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING